INOZYME PHARMA INC (INZY) Stock Income Statement
NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 104.03M | 75.64M | 68.68M | 56.65M | 57.04M | |||
| Research and Development | 83.23M | 54.85M | 47.85M | 37.72M | 46.49M | |||
| Selling, General, and Administrative Expenses | 20.80M | 20.80M | 20.83M | 18.93M | 10.55M | |||
| Operating Income | -104.03M | -75.64M | -68.68M | -56.65M | -57.04M | |||
| Interest Income/Expense | 2.11M | 4.50M | 1.93M | 210.00K | 370.00K | |||
| Other Income/Expense | -102.00K | -28.00K | -320.00K | -190.00K | 250.00K | |||
| Income Before Taxes | -102.02M | -71.17M | -67.06M | -56.62M | -56.42M | |||
| Income Tax | 0.00 | N/A | N/A | N/A | N/A | |||
| Net Income | -102.02M | -71.17M | -67.06M | -56.62M | -56.42M | |||
| EBITDA | -103.29M | -74.81M | -67.94M | -55.98M | -56.82M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.62 | -1.37 | -1.78 | -2.40 | -2.41 | |||
| Non GAAP EPS | -1.62 | -1.37 | -1.89 | -2.39 | N/A | |||
| Statistics | ||||||||
All data in USD